Related Experiment Video
Updated: Jul 22, 2026
08:08
Optimized Protocol for Efficient Transfection of Dendritic Cells without Cell Maturation
Published on: July 8, 2011
Development of a Langerhans cell-targeted gene therapy format using a dendritic cell-specific promoter
A Morita1, K Ariizumi, R Ritter
1Department of Dermatology, University of Texas Southwestern Medical Center, Dallas 75390, USA.
Gene Therapy
|March 15, 2002
Summary
Researchers developed a novel gene therapy targeting Langerhans cells (LCs) in the skin. This approach uses a specific promoter to genetically modify LCs in situ, potentially enabling new immune responses.
Area of Science:
- Immunology
- Dermatology
- Gene Therapy
Background:
- Langerhans cells (LCs) are skin-resident dendritic cells (DCs) crucial for initiating skin immune responses.
- Targeting LCs for genetic manipulation is a potential strategy for modulating skin immunity.
Purpose of the Study:
- To develop an in situ gene therapy approach for genetically manipulating Langerhans cell function.
- To identify and utilize a DC-specific promoter for targeted gene expression in LCs.
Main Methods:
- Isolation and characterization of the dectin-2 promoter (pDec2) for DC-specific activity.
- Delivery of pDec2-driven reporter genes (luciferase, EGFP) to mouse skin via gene gun.
- Analysis of gene expression, LC maturation, migration, and immune response induction.
Main Results:
- The dectin-2 promoter (pDec2) demonstrated significant transcriptional activity specifically in epidermal DCs.
- Gene gun delivery resulted in exclusive expression in Langerhans cells (IA+ population) within the epidermis.
- LCs exhibited mature DC features, migrated to lymph nodes, and induced EGFP-specific cellular immune responses.
Conclusions:
- A novel LC-targeted gene therapy format was successfully established using in situ genetic manipulation.
- The combination of gene gun delivery and the dectin-2 promoter enables targeted gene expression in LCs.
- This approach holds promise for developing novel immune responses by genetically modifying skin-resident LCs.
